<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">World Allergy Organ J</journal-id><journal-id journal-id-type="iso-abbrev">World Allergy Organ J</journal-id><journal-id journal-id-type="publisher-id">wox</journal-id><journal-title-group><journal-title>The World Allergy Organization Journal</journal-title></journal-title-group><issn pub-type="epub">1939-4551</issn><publisher><publisher-name>World Allergy Organization Journal</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3513088</article-id><article-id pub-id-type="doi">10.1097/01.WOX.0000411947.74342.3e</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts of the XXII World Allergy Congress</subject></subj-group><subj-group subj-group-type="heading"><subject>Poster Symposium</subject></subj-group><series-title>Asthma Treatment</series-title></article-categories><title-group><article-title>190&#x02003;Effect of Mometasone Furoate/Formoterol Combination Therapy on Nocturnal Awakenings in Subjects With Persistent Asthma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pearlman</surname><given-names>David</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nathan</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Meltzer</surname><given-names>Eli</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Nolte</surname><given-names>Hendrik</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Weinstein</surname><given-names>Steven</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Colorado Allergy and Asthma Centers, Denver, CO</aff><aff id="aff2"><label>2</label>Asthma &#x00026; Allergy Associates, P.C. and Research Center, Colorado Springs, CO</aff><aff id="aff3"><label>3</label>Allergy and Asthma Medical Group &#x00026; Research Center, San Diego, CA</aff><aff id="aff4"><label>4</label>Merck Research Laboratories, Kenilworth, NJ.</aff><pub-date pub-type="epub"><day>17</day><month>2</month><year>2012</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2012</year></pub-date><volume>5</volume><issue>Suppl 2</issue><issue-title>Abstracts of the XXII World Allergy Congress, 4&#x02013;8 December, 2012 Canc&#x000fa;n, M&#x000e9;xico</issue-title><fpage seq="a">S80</fpage><lpage>S80</lpage><permissions><copyright-statement>Copyright &#x000a9; 2012 by World Allergy Organization</copyright-statement><copyright-year>2012</copyright-year></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="waoj-5-S80.pdf"/><abstract><sec><title>Background</title><p>Asthmatics often report asthma-related nocturnal awakenings. These sleep interruptions may have a significant impact on patients' quality of life. We characterized the effect of mometasone furoate/formoterol (MF/F) administered via pressured metered-dose inhaler on incidence of nocturnal awakenings requiring short-acting &#x003b2;<sub>2</sub>-agonists (SABAs).</p></sec><sec><title>Methods</title><p>MF/F's effect on nocturnal awakenings requiring SABA was characterized across 3 phase III efficacy trials (baseline = number of nights with awakenings in week before first dose; endpoint = number of nights/wk with awakenings averaged across the 26-week treatment period). Subjects were asthmatics previously treated with low- (n=746), medium- (n=781) or high-dose (n=728) inhaled corticosteroids at various doses. Subjects in the MF/F 100/10 &#x003bc;g BID study were randomized to 26 weeks of twice-daily (BID) treatment with MF/F 100/10 &#x003bc;g, MF 100 &#x003bc;g, F 10 &#x003bc;g, or placebo; subjects in the MF/F 200/10 &#x003bc;g BID study to 26 weeks of BID treatment with MF/F 200/10 &#x003bc;g, MF 200 &#x003bc;g, F 10 &#x003bc;g, or placebo; and subjects in the MF/F 400/10 &#x003bc;g BID study to 12 weeks of BID treatment with MF/F 400/10 &#x003bc;g, MF/F 200/10 &#x003bc;g, or MF 400 &#x003bc;g. All treatments were delivered via a metered dose inhaler.</p></sec><sec><title>Results</title><p>Baseline awakenings ranged from 0.84&#x02013;1.05, 1.05&#x02013;1.26, and 1.33&#x02013;1.61 nights/wk in the MF/F 100/10 &#x003bc;g BID, MF/F 200/10 &#x003bc;g BID, and MF/F 400/10 &#x003bc;g BID studies, respectively. In the MF/F 100/10 &#x003bc;g BID study, nocturnal awakenings were reduced by MF/F = &#x02013;0.42, MF = &#x02013;0.21, F = &#x02013;0.21, and placebo = 0.14 nights/wk; corresponding changes in the MF/F 200/10 &#x003bc;g BID study were &#x02013;0.56, &#x02013;0.35, +0.07 and 0.00 nights/wk, respectively. In each of these placebo-controlled studies, MF/F was superior to placebo (<italic>P</italic> &#x0003c; .001) and F (<italic>P</italic> &#x02264;.035); MF was also superior to F and placebo. In the MF/F 400/10 &#x003bc;g BID study, awakenings were reduced by &#x02013;0.70, &#x02013;0.70 and &#x02013;0.35 nights/wk by MF/F 200/10 &#x003bc;g, MF/F 400/10 &#x003bc;g, and MF 400 &#x003bc;g, respectively; both MF/F treatments were superior to MF (<italic>P</italic> &#x02264;0.006).</p></sec><sec><title>Conclusions</title><p>These results provide evidence that validates the role of MF/F in reducing nocturnal asthma symptoms in patients with moderate to severe persistent asthma and supports the efficacy of MF/F compared with that of placebo and F.</p></sec></abstract></article-meta></front></article>